HNSA — Hansa Biopharma AB Share News
0.000.00%
Last trade - 00:00- SEK4.77bn
- SEK4.38bn
- SEK222.27m
Brief: Hansa Biopharma Submits BLA To FDA For Imlifidase In Desensitization For Kidney Transplantation
Hansa Biopharma Shares Plunge After Anti-GBM Trial Misses Primary Endpoint
Europe Research Roundup: Admiral, Hunting, Mowi
Brief: Hansa Biopharma Says Phase 3 Trial Did Not Meet Primary Endpoint
Brief: Hansa Biopharma Q3 Net Income SEK -148.3 Million
Brief: Hansa Biopharma Raises $71 Million Through Directed Share Issue
Brief: Hansa Biopharma AB Announces USD 60 Million Share Issue
Brief: Hansa Biopharma Says Imlifidase Successfully Meets Primary Endpoint In Pivotal Us Phase 3 Confides Trial In Kidney Transplantation
Brief: Hansa Biopharma Announces Supportive Data From Treatment With Imlifidase Prior To Administration Of Gene Therapy For Duchenne Muscular Dystrophy
Brief: Hansa Biopharma Presents Positive Outcomes Of Study Of Imlifidase In Kidney Transplantation
Brief: Hansa Biopharma Says To Issue 10.5 Million New Ordinary Shares At SEK 22.00 Each
Brief: Hansa Biopharma Says Intends To Carry Out Directed Share Issue Of Approximately 10 Million Shares
Brief: Hansa Biopharma Says Restructuring To Optimize Resource Allocation, Save 40-50 SEK Mln Annually
Brief: Hansa Biopharma Q1 Net Income SEK -37.1 Million
Brief: Hansa Biopharma Appoints Renée Aguiar-Lucander As CEO
Brief: Hansa Biopharma Q4 Net Income SEK -276.4 Million
Brief: Hansa Biopharma Announces Positive Full Results From 15-Hmedides-09 Phase 2 Study And Comparative Analysis Of Imlifidase In Patients With Guillain-Barré Syndrome
Brief: Hansa Biopharma Announces Positive Full Results From 15-Hmedides-09 Phase 2 Study
Brief: Genethon, Hansa Biopharma Start Phase 2 Trial Of Imlifidase